Ask AI
ProCE Banner Activity

Adverse Management and Supportive Care in Myelofibrosis Treatment

Slideset

Selecting and sequencing JAK inhibitors in myelofibrosis requires balancing disease risk, symptom and spleen burden, cytopenias, prior treatment response, comorbidities, and patient preferences. This slideset examines evidence-based approaches to first- and later-line therapy, recognition of ruxolitinib resistance or intolerance, and transition strategies when treatment response is inadequate or adverse events limit therapy. Learners will also review practical monitoring, supportive care, and adverse event management considerations for ruxolitinib, fedratinib, pacritinib, and momelotinib to help individualize treatment, maintain clinical benefit, and reduce avoidable gaps in care.

Released: August 18, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education In partnership with Smart Patients, Inc.

ProCE Banner

Supporters

This educational activity is supported by independent medical education grants from GSK, Incyte Corporation, and Sobi.

GSK

Incyte Corporation

Sobi

Partners

Smart Patients, Inc.

ProCE Banner

Target Audience

This activity is intended for oncologists, hematologists, nurses, pharmacists, and other healthcare professionals who care for patients with myelofibrosis. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop evidence-based supportive care strategies to manage treatment-related adverse AEs in patients with MF

Additional Disclosures

Generative artificial intelligence (AI) tools were used for drafting educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.